Skip to main content
Full access
Communications and Updates
Published Online: 1 July 2014

Electroconvulsive Therapy is a Standard Treatment; Ketamine is Not (Yet)

To The Editor: Alan Schatzberg’s commentary in the March issue, “A Word to the Wise About Ketamine” (1), urges caution in the clinical use of ketamine pending further research and data collection. We agree with this position and would like to share our clinical experience with seriously depressed patients who have received ketamine infusions prior to electroconvulsive therapy (ECT) referral. In the last year, we have seen at least half a dozen patients who, when they presented for ECT consultation, gave histories of having had either single or repeated ketamine infusions at a private anesthesiologist’s office in New York City. These patients had either no, or very transient, antidepressant benefit from the ketamine or unpleasant adverse effects (mainly dissociative); they were subsequently referred by their psychiatrists for consideration of ECT. Most of these patients were profoundly depressed, and some were suicidal. If a ketamine challenge is to become a standard step in the treatment algorithm for treatment-resistant depression, the risks of not just the ketamine itself, but the delay in definitive treatment, must be taken into account.
Seriously depressed patients who have failed to respond to one or more antidepressant medication trials should be referred for ECT consultation, sooner rather than later, to ensure optimal outcomes. Suicide risk in this population is elevated, as is the potential for ongoing medical morbidity, not to mention the continued suffering from the depressive episode itself. A recent study (2) comparing three ketamine infusions with three ECT treatments in 1 week touted ketamine as a superior treatment and received considerable media attention (3). A reasonable interpretation of that research is that it replicated the finding of a signal of early antidepressant response with ketamine. However, ketamine remains completely unproven as a definitive treatment for a major depressive episode. Seriously ill psychiatric patients are often desperate for dramatic cures; their health care providers, acknowledging that our current treatments are often lacking, are also eager for the newest breakthroughs. Such desperation and enthusiasm should not cloud our clinical judgment; proven, evidence-based treatments, including ECT for seriously depressed patients, should be offered before unproven, experimental approaches, no matter how “in vogue” those approaches may be.

References

1.
Schatzberg AF: A word to the wise about ketamine. Am J Psychiatry 2014; 171:262–264
2.
Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH: Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014; 215:355–361
3.
Arehart-Treichel J: Ketamine outperforms ECT in depression study. Psychiatr News, Jan 2014, p 17

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 796
PubMed: 24980176

History

Accepted: April 2014
Published online: 1 July 2014
Published in print: July 2014

Authors

Affiliations

Charles H. Kellner, M.D.
From the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, and the Department of Psychiatry, Lutheran Medical School, Brooklyn, New York.
Robert M. Greenberg, M.D.
From the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, and the Department of Psychiatry, Lutheran Medical School, Brooklyn, New York.
Gabriella M. Ahle
From the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, and the Department of Psychiatry, Lutheran Medical School, Brooklyn, New York.
Lauren S. Liebman
From the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, and the Department of Psychiatry, Lutheran Medical School, Brooklyn, New York.

Competing Interests

Dr. Kellner receives grant support from NIMH, honoraria from the North Shore-LIJ Health System, UpToDate, and Psychiatric Times, and royalties from Cambridge University Press. Dr. Greenberg receives grant support from NIMH. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share